Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism

被引：27

作者：

Arachchillage, D. R. J. ^{[1
]}

Efthymiou, M. ^{[1
]}

Mackie, I. J. ^{[1
]}

Lawrie, A. S. ^{[1
]}

Machin, S. J. ^{[1
]}

Cohen, H. ^{[1
,2
]}

机构：

[1] UCL, Dept Haematol, Haemostasis Res Unit, London WC1E 7HX, England

[2] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

来源：

THROMBOSIS RESEARCH | 2015年 / 135卷 / 02期

关键词：

Rivaroxaban; Warfarin; thrombin generation; thrombin-antithrombin complex; prothrombin fragment 1.2; D-dimer; THROMBIN GENERATION; ANTITHROMBIN-III; ORAL RIVAROXABAN; D-DIMER; PREDICTION; GUIDELINES; INTENSITY; PLASMA; ASSAYS; F1+2;

D O I：

10.1016/j.thromres.2014.11.037

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Rivaroxaban is non-inferior to warfarin for the treatment of venous thromboembolism, with regard to clinical efficacy and safety. The ex-vivo effects of warfarin versus therapeutic dose rivaroxaban on in-vivo markers of coagulation activation and thrombin generation remain undefined. The aim of this study was to compare the effects of warfarin and therapeutic dose rivaroxaban on ex-vivo thrombin generation (TG), and the in-vivo markers of coagulation activation, prothrombin fragment 1.2 (F1.2), thrombin-antithrombin complex (TAT), and D-dimer. Methods: Eighty-five patients with venous thromboembolism were studied, 45 on warfarin, target INR 2.5 and 40 on rivaroxaban 20 mg once daily. Results: Anticoagulation was in therapeutic range in 71% (32/45) warfarin and 65% (26/40) rivaroxaban treated patients. 8 patients on warfarin and 9 patients on rivaroxaban had subtherapeutic INR and rivaroxaban levels respectively. Both rivaroxaban and warfarin reduced endogenous thrombin potential (ETP) and peak thrombin, and prolonged lag time and time to peak, compared to normal controls (p < 0.0001). The lag time and time to peak TG were longer, and peak thrombin was lower in patients receiving rivaroxaban (p < 0.0001) compared with warfarin, although warfarin-treated patients had lower ETP (p = 0.0008). In-vivo coagulation activation markers were within the normal ranges in all rivaroxaban-treated patients (including those with levels considered to be subtherapeutic) and in 37/45 warfarin-treated patients who had an INR >= 2.0. The warfarin-treated patients with subtherapeutic INRs exhibited slightly raised F1.2 and/or TAT. Conclusion: In conclusion, both rivaroxaban and warfarin provided effective anticoagulation, as assessed by inhibition of TG and makers of in-vivo coagulation activation. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：388 / 393

页数：6

共 36 条

[1] The thrombogram in rare inherited coagulation disorders:: Its relation to clinical bleeding [J].

Al Dieri, R ;

Peyvandi, F ;

Santagostino, E ;

Giansily, M ;

Mannucci, PM ;

Schved, JF ;

Béguin, S ;

Hemker, HC .

THROMBOSIS AND HAEMOSTASIS, 2002, 88 (04) :576-582

[2]

[Anonymous], 2014, XARELTO 20MG FILM CO

[3] Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].

Bauersachs, Rupert ;

Berkowitz, Scott D. ;

Brenner, Benjamin ;

Buller, Harry R. ;

Decousus, Herve ;

Gallus, Alex S. ;

Lensing, Anthonie W. ;

Misselwitz, Frank ;

Prins, Martin H. ;

Raskob, Gary E. ;

Segers, Annelise ;

Verhamme, Peter ;

Wells, Phil ;

Agnelli, Giancarlo ;

Bounameaux, Henri ;

Cohen, Alexander ;

Davidson, Bruce L. ;

Piovella, Franco ;

Schellong, Sebastian .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510

[4] High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study [J].

Besser, M. ;

Baglin, C. ;

Luddington, R. ;

Vlieg, A. van Hylckama ;

Baglin, T. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (10) :1720-1725

[5] Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation [J].

Bloemen, Saartje ;

Hemker, H. Coenraad ;

Al Dieri, Raed .

HAEMATOLOGICA, 2013, 98 (04) :549-554

[6] The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma [J].

Boström, SL ;

Hansson, GFH ;

Sarich, TC ;

Wolzt, M .

THROMBOSIS RESEARCH, 2004, 113 (01) :85-91

[7] Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment [J].

Brodin, E. ;

Seljeflot, I. ;

Arnesen, H. ;

Hurlen, M. ;

Appelbom, H. ;

Hansen, J. B. .

THROMBOSIS RESEARCH, 2009, 123 (04) :573-579

[8] Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism [J].

Buller, Harry R. ;

Prins, Martin H. ;

Lensing, Anthonie W. A. ;

Decousus, Herve ;

Jacobson, Barry F. ;

Minar, Erich ;

Chlumsky, Jaromir ;

Verhamme, Peter ;

Wells, Phil ;

Agnelli, Giancarlo ;

Cohen, Alexander ;

Berkowitz, Scott D. ;

Bounameaux, Henri ;

Davidson, Bruce L. ;

Misselwitz, Frank ;

Gallus, Alex S. ;

Raskob, Gary E. ;

Schellong, Sebastian ;

Segers, Annelise .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (14) :1287-1297

[9] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].

COCKCROFT, DW ;

GAULT, MH .

NEPHRON, 1976, 16 (01) :31-41

[10] SUPPRESSION OF HEMOSTATIC SYSTEM ACTIVATION BY ORAL ANTICOAGULANTS IN THE BLOOD OF PATIENTS WITH THROMBOTIC DIATHESES [J].

CONWAY, EM ;

BAUER, KA ;

BARZEGAR, S ;

ROSENBERG, RD .

JOURNAL OF CLINICAL INVESTIGATION, 1987, 80 (06) :1535-1544

← 1 2 3 4 →